Bayer picks up radiotherapeutics biotech to prop up dwindling sales in prostate cancer program

Bayer picks up radiotherapeutics biotech to prop up dwindling sales in prostate cancer program

Source: 
Fierce Biotech
snippet: 

Amid sliding sales for prostate cancer drug Xofigo, Bayer will bolster its portfolio of targeted alpha therapies with the acquisition of radiotherapeutics biotech Noria Therapeutics and subsidiary PSMA Therapeutics.